FTH

7.9808.17%
LC

Lewis clayton Cantley

Scientific Co-Founder

Dr. Lewis Clayton Cantley, also known as lew., Ph.D. is Founder of Faeth Therapeutics, Inc. He is Scientific Co-Founder at Faeth Therapeutics, Inc. since 2026. He is Founder and Chair of Scientific Advisory Committee at Volastra Therapeutics, Inc. He serves as Scientific Advisor of Scorpion Therapeutics, Inc. He was Member of Scientific Advisory Board at Totus Medicines Inc. until July 2025. He is Co-Founder and Chair of Scientific Advisory Board of Larkspur Biosciences Inc. He serves as Member of Scientific Advisory Board at Sprint Bioscience AB (publ). He is Co-Founder of Agios Pharmaceuticals Inc. Dr. Cantley serves as Co-Editor-In-Chief for the AACRs newest journal, Cancer Discovery. Dr. Cantley Co-founded Petra Pharma Corporation in 2016 and serves as its Member of Scientific Advisory Board since July 27, 2017. He is an Associate Editor of the Journal of Cell Biology. Dr. Cantley serves as Member of Scientific Advisory Board at CervoMed Inc. (Formerly, EIP Pharma, Inc.). He has biomedical research experience. Dr. Cantley serves as a Member of Scientific Advisory Board at Ontario Institute For Cancer Research. He serves as a Scientific Advisory Board Member at Aveo Pharmaceuticals, Inc. He had been a Director of American Association for Cancer Research since April 2, 2012. Dr. Cantley serves as a Director of the Beth Israel Deaconess Cancer Center in Boston. He serves as a Member of the Editorial Board at Cell. He served as a Member of Scientific Advisory Board at Vertex Pharmaceuticals Incorporated since July 2005. He served as a Director of Agios Pharmaceuticals, Inc. from August 2007 to December 31, 2017. He was a Member of Scientific Advisory Board at Agios Pharmaceuticals, Inc. until August 2024. He served as a Member of Medical Advisory Board at TransMolecular Inc., since October 2007. Dr. Cantley serves as the Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. He joined Weill Cornell in 2012. He served as a Professor at Tufts University School of Medicine from 1985 to 1992 and at Harvard Medical School since 1992. He served as a Professor of Cell Biology and Systems Biology at Harvard Medical School. Dr. Cantley focused on the structure and mechanism of enzymes that transport small molecules across cell membranes and he pioneered the application of fluorescence resonance energy transfer (FRET). In 1980, Dr. Cantley focused his research on biochemical mechanisms of cellular responses to hormones and growth factors. He is a foremost expert in understanding the biochemical pathways linking cancer and energy metabolism, discovered the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. He focused on characterizing the mechanism by which PI3K is activated by growth factors and oncogenes and elucidating pathways downstream of PI3K, including the AKT/PKB signaling pathway. He is exploring the role of the PI3K pathway in cancer and diabetes by developing mouse models in which genes for enzymes in this pathway are altered. He was elected to the American Academy of Arts and Sciences in 1999 and to Member of the National Academy of Sciences in 2001. He was awarded the Pezcoller Foundation-AACR International Award for Cancer Research in 2005. Among his other awards are the ASBMB Avanti Award for Lipid Research in 1998, the Heinrich Weiland Preis for Lipid Research in 2000 and the Caledonian Prize from the Royal Society of Edinburgh in 2002. He is a Professor of Cell Biology and Systems Biology at Harvard Medical School and Chief of the Division of Signal Transduction at Beth Israel Deaconess Medical Center. Dr. Cantley joined the Department of Biochemistry and Molecular Biology at Harvard in 1978 as its Assistant Professor. He graduated suma cum laude with a B.S. in Chemistry from W.V. Wesleyan College in 1971 and a PhD in Biophysical Chemistry from Cornell University in 1975. He did Postdoctoral Research at Harvard from 1975 to 1978.

Positions